Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

0.67 

0.01 1.0%

as of Mar 23 '23

52 Week Range:

0.63 115.40


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Equity (BVPS) 12.02
11.78
11.21
10.40
9.26
8.41
8.07
7.42
7.07
6.82
19.01
growth rate -2.0% -4.8% -7.2% -11.0% -9.2% -4.0% -8.1% -4.7% -3.5% 178.7%
Earnings BIT 7,614.97
4,752.43
6,842.00
4,203.00
4,071.00
3,906.00
3,686.00
1,731.00
3,068.00
4,148.00
4,569.00
growth rate -37.6% 44.0% -38.6% -3.1% -4.1% -5.6% -53.0% 77.2% 35.2% 10.2%
Avg.PE 6.28
9.43
28.90
54.75
18.43
16.76
20.19
36.71
74.95
30.67
112.02
growth rate 50.2% 206.5% 89.5% -66.3% -9.1% 20.5% 81.8% 104.2% -59.1% 265.2%
ROA 18.32
11.84
4.67
2.15
4.76
5.71
4.77
3.48
2.19
4.99
0.13
growth rate -35.4% -60.6% -54.0% 121.4% 20.0% -16.5% -27.0% -37.1% 127.9% -97.4%
ROE 42.98
26.81
10.89
5.75
14.82
20.99
20.13
15.71
10.43
22.23
0.41
growth rate -37.6% -59.4% -47.2% 157.7% 41.6% -4.1% -22.0% -33.6% 113.1% -98.2%
ROIC 31.78
21.20
8.63
6.73
11.71
14.58
12.46
9.79
7.35
12.31
2.09
growth rate -33.3% -59.3% -22.0% 74.0% 24.5% -14.5% -21.4% -24.9% 67.5% -83.0%
Cur. Ratio 1.49
1.37
1.27
0.96
1.08
0.87
0.80
0.95
0.85
0.96
1.16
growth rate -8.1% -7.3% -24.4% 12.5% -19.4% -8.1% 18.8% -10.5% 12.9% 20.8%
Quick Ratio 1.31
1.08
1.11
0.82
0.90
0.68
0.57
0.69
0.61
0.65
0.64
growth rate -17.6% 2.8% -26.1% 9.8% -24.4% -16.2% 21.1% -11.6% 6.6% -1.5%
Leverage 2.27
2.26
2.41
2.99
3.25
4.21
4.23
4.86
4.68
4.27
2.68
growth rate -0.4% 6.6% 24.1% 8.7% 29.5% 0.5% 14.9% -3.7% -8.8% -37.2%
Balance Sheet Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Acct.Receivable 8,923.00
7,334.00
6,802.00
6,163.00
6,599.00
4,764.00
4,452.00
4,837.00
5,181.00
5,651.00
8,795.00
growth rate -17.8% -7.3% -9.4% 7.1% -27.8% -6.6% 8.7% 7.1% 9.1% 55.6%
Acct.Payable 2,155.00
2,449.00
2,499.00
3,492.00
3,469.00
1,680.00
2,285.00
1,720.00
1,774.00
2,350.00
2,824.00
growth rate 13.6% 2.0% 39.7% -0.7% -51.6% 36.0% -24.7% 3.1% 32.5% 20.2%
Cur.Assets 23,506.00
19,048.00
20,335.00
16,697.00
16,007.00
13,262.00
13,150.00
15,591.00
15,563.00
19,544.00
26,244.00
growth rate -19.0% 6.8% -17.9% -4.1% -17.2% -0.8% 18.6% -0.2% 25.6% 34.3%
Total Assets 52,830.00
53,534.00
55,899.00
58,595.00
60,056.00
62,526.00
63,354.00
60,651.00
61,377.00
66,729.00
105,363.00
growth rate 1.3% 4.4% 4.8% 2.5% 4.1% 1.3% -4.3% 1.2% 8.7% 57.9%
Cash 7,571.00
7,701.00
9,217.00
6,360.00
6,240.00
5,018.00
3,324.00
4,831.00
5,369.00
7,832.00
6,329.00
growth rate 1.7% 19.7% -31.0% -1.9% -19.6% -33.8% 45.3% 11.1% 45.9% -19.2%
Inventory 1,852.00
2,061.00
1,909.00
1,960.00
2,143.00
2,334.00
3,035.00
2,890.00
3,193.00
4,024.00
8,983.00
growth rate 11.3% -7.4% 2.7% 9.3% 8.9% 30.0% -4.8% 10.5% 26.0% 123.2%
Cur.Liabilities 15,752.00
13,903.00
16,051.00
17,330.00
14,869.00
15,256.00
16,383.00
16,292.00
18,117.00
20,307.00
22,594.00
growth rate -11.7% 15.5% 8.0% -14.2% 2.6% 7.4% -0.6% 11.2% 12.1% 11.3%
Liabilities 29,364.00
29,588.00
32,646.00
38,949.00
41,547.00
45,857.00
46,712.00
46,607.00
46,781.00
51,091.00
66,076.00
growth rate 0.8% 10.3% 19.3% 6.7% 10.4% 1.9% -0.2% 0.4% 9.2% 29.3%
LT Debt 7,338.00
9,347.00
8,517.00
8,337.00
14,110.00
16,513.00
17,387.00
19,201.00
17,894.00
19,804.00
29,717.00
growth rate 27.4% -8.9% -2.1% 69.3% 17.0% 5.3% 10.4% -6.8% 10.7% 50.1%
Equity 14,310.24
14,608.80
23,224.00
19,627.00
18,490.00
14,854.00
14,960.00
12,468.00
13,127.00
15,622.00
39,268.00
growth rate 2.1% 59.0% -15.5% -5.8% -19.7% 0.7% -16.7% 5.3% 19.0% 151.4%
Common Shares 1,367.00
1,264.00
1,254.00
1,264.00
1,265.00
1,266.00
1,267.00
317.00
328.00
328.00
387.00
growth rate -7.5% -0.8% 0.8% 0.1% 0.1% 0.1% -75.0% 3.5% 0.0% 18.0%
Cash Flow Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Capital Expenditures 839.00
672.00
742.00
1,012.00
1,328.00
1,446.00
1,326.00
1,043.00
979.00
961.00
1,091.00
growth rate -19.9% 10.4% 36.4% 31.2% 8.9% -8.3% -21.3% -6.1% -1.8% 13.5%
Cash Dividends 2,317.12
2,256.17
3,461.00
3,521.00
3,486.00
3,561.00
3,519.00
3,484.00
3,592.00
3,572.00
3,856.00
growth rate -2.6% 53.4% 1.7% -1.0% 2.2% -1.2% -1.0% 3.1% -0.6% 8.0%
Cash From OA 7,821.00
6,948.00
7,400.00
7,058.00
3,324.00
4,145.00
3,578.00
2,618.00
2,969.00
4,799.00
5,963.00
growth rate -11.2% 6.5% -4.6% -52.9% 24.7% -13.7% -26.8% 13.4% 61.6% 24.3%
FCF per Share 3.22
1.14
2.87
2.35
1.00
0.35
1.66
-0.08
0.79
1.08
2.34
growth rate -64.6% 151.8% -18.1% -57.5% -65.0% 374.3% -100.0% 100.0% 36.7% 116.7%
Sale Purchase of Stock 482.00
279.00
43.00
47.00
43.00
growth rate -42.1% -84.6% 9.3% -8.5%
FCF 6,524.00
2,329.00
5,342.00
4,306.00
536.00
1,831.00
1,958.00
1,247.00
509.00
2,193.00
3,763.00
growth rate -64.3% 129.4% -19.4% -87.6% 241.6% 6.9% -36.3% -59.2% 330.8% 71.6%
Income Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Sales 33,591.00
27,973.00
25,806.00
26,547.00
24,708.00
23,002.00
22,465.00
22,090.00
24,384.00
26,617.00
37,417.00
growth rate -16.7% -7.8% 2.9% -6.9% -6.9% -2.3% -1.7% 10.4% 9.2% 40.6%
Op.Income 9,950.00
6,270.00
6,842.00
4,203.00
4,071.00
3,906.00
3,686.00
1,731.00
3,068.00
4,148.00
4,569.00
growth rate -37.0% 9.1% -38.6% -3.1% -4.1% -5.6% -53.0% 77.2% 35.2% 10.2%
IBT 7,613.13
4,706.88
3,267.00
1,246.00
3,069.00
3,552.00
2,227.00
1,993.00
1,548.00
3,916.00
-265.00
growth rate -38.2% -30.6% -61.9% 146.3% 15.7% -37.3% -10.5% -22.3% 153.0% -100.0%
Net Income 9,950.00
6,270.00
2,556.00
1,233.00
2,825.00
3,499.00
3,001.00
2,155.00
1,335.00
3,196.00
112.00
growth rate -37.0% -59.2% -51.8% 129.1% 23.9% -14.2% -28.2% -38.1% 139.4% -96.5%
EPS 7.25
4.94
2.04
0.98
2.23
2.76
2.37
1.70
1.03
2.44
0.08
growth rate -31.9% -58.7% -52.0% 127.6% 23.8% -14.1% -28.3% -39.4% 136.9% -96.7%
Gross Profit 27,488.00
22,716.00
20,671.00
20,812.00
20,220.00
19,006.00
18,328.00
17,586.00
19,536.00
21,371.00
27,610.00
growth rate -17.4% -9.0% 0.7% -2.8% -6.0% -3.6% -4.1% 11.1% 9.4% 29.2%
R&D 3,399.96
3,227.59
4,281.00
5,001.00
5,660.00
5,679.00
5,455.00
5,299.00
5,349.00
6,123.00
8,580.00
growth rate -5.1% 32.6% 16.8% 13.2% 0.3% -3.9% -2.9% 0.9% 14.5% 40.1%

Quarterly Statements

Item Name Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Earnings BIT 1,197.00
82.00
1,878.00
2,842.00
2,021.00
growth rate -93.2% 2,190.2% 51.3% -28.9%
Balance Sheet Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Acct.Receivable 6,842.00
8,854.00
8,795.00
9,050.00
9,612.00
growth rate 29.4% -0.7% 2.9% 6.2%
Acct.Payable 16,840.00
17,759.00
2,824.00
17,040.00
16,983.00
growth rate 5.5% -84.1% 503.4% -0.3%
Cur.Assets 27,274.00
26,691.00
26,244.00
22,647.00
20,917.00
growth rate -2.1% -1.7% -13.7% -7.6%
Total Assets 73,641.00
107,221.00
105,363.00
100,273.00
96,579.00
growth rate 45.6% -1.7% -4.8% -3.7%
Cash 15,567.00
7,067.00
6,329.00
5,762.00
4,817.00
growth rate -54.6% -10.4% -9.0% -16.4%
Inventory 4,762.00
10,528.00
8,983.00
7,624.00
6,220.00
growth rate 121.1% -14.7% -15.1% -18.4%
Cur.Liabilities 22,222.00
23,649.00
22,594.00
22,740.00
21,815.00
growth rate 6.4% -4.5% 0.7% -4.1%
Liabilities 57,948.00
67,309.00
66,076.00
63,914.00
60,628.00
growth rate 16.2% -1.8% -3.3% -5.1%
LT Debt 25,598.00
29,724.00
29,717.00
28,868.00
27,393.00
growth rate 16.1% 0.0% -2.9% -5.1%
Equity 15,676.00
39,744.00
39,268.00
36,340.00
35,932.00
growth rate 153.5% -1.2% -7.5% -1.1%
Common Shares 328.00
387.00
387.00
387.00
387.00
growth rate 18.0% 0.0% 0.0% 0.0%
Cash Flow Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Capital Expenditures 288.00
260.00
323.00
219.00
253.00
growth rate -9.7% 24.2% -32.2% 15.5%
Cash Dividends 1,387.00
1,387.00
2,971.00
2,971.00
growth rate 0.0% 114.2% 0.0%
Cash From OA 892.00
1,719.00
1,418.00
3,232.00
1,248.00
growth rate 92.7% -17.5% 127.9% -61.4%
Sale Purchase of Stock
growth rate
FCF 604.00
1,459.00
1,095.00
3,013.00
995.00
growth rate 141.6% -25.0% 175.2% -67.0%
Income Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Sales 8,220.00
9,866.00
12,011.00
11,390.00
10,771.00
growth rate 20.0% 21.7% -5.2% -5.4%
Op.Income 1,197.00
82.00
1,878.00
2,842.00
2,021.00
growth rate -93.2% 2,190.2% 51.3% -28.9%
IBT 764.00
-2,001.00
-636.00
553.00
247.00
growth rate -100.0% 0.0% 100.0% -55.3%
Net Income 550.00
-1,652.00
-347.00
386.00
360.00
growth rate -100.0% 0.0% 100.0% -6.7%
EPS
growth rate
Gross Profit 6,035.00
6,317.00
9,795.00
9,111.00
8,942.00
growth rate 4.7% 55.1% -7.0% -1.9%
R&D 1,810.00
2,315.00
2,755.00
2,211.00
2,417.00
growth rate 27.9% 19.0% -19.8% 9.3%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

D (43.65)

YOY Growth Grade:

F (15.73)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 0.52 0.31 0.23
EPS / Growth 15.0% 2.18 14.1%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 37.2%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 14.1% 22.1% 22.1%
Future PE 0.23 0.42 14.99
Future EPS 8.15 16.07 16.07
Value Price
MOS %
0.46
-30.7%
1.68
151.4%
59.54
8,786.5%
MOS Price 0.23 0.84 29.77
IRT 0.00 0.00 0.00

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.